Global Oligonucleotide Synthesis Market Report 2021: Market is Poised for Explosive Growth as Gene Technology Moves into Mainstream Healthcare, Food Production and, Even, Data Storage
August 03, 2021 06:58 ET
|
Research and Markets
Dublin, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Global $34.31 Billion Cell and Gene Therapy Markets, 2015-2020, 2025F, 2030F
July 12, 2021 04:38 ET
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
June 26, 2021 11:15 ET
|
Intellia Therapeutics, Inc.
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean...
North America Cell Therapy (Allogeneic and Autologous) Market Report 2021-2027
June 25, 2021 06:13 ET
|
Research and Markets
Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "North America Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type, Product, Technology, Application, and End...
CRISPR and Cas Genes Markets, 2028 by Product & Service (Vector-based Cas, DNA-free Cas), Application (Biomedical, Agriculture)
June 16, 2021 06:08 ET
|
Research and Markets
Dublin, June 16, 2021 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by Product & Service (Vector-based Cas, DNA-free Cas), by Application...
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
June 04, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...
Global Cell Therapy Bioprocessing Market Report 2021-2028: Digital Biomanufacturing to Gain Prominence
June 03, 2021 05:58 ET
|
Research and Markets
Dublin, June 03, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Cell Type, End User, and Geography" report has...
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
Outlook on the Cell Therapy Global Market to 2027 - by Therapy Type, Product, Technology, Application, End-user and Geography
March 31, 2021 05:18 ET
|
Research and Markets
Dublin, March 31, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography"...
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 30, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...